WAYNETOWN, Ind. — Tony Manion doesn't miss a workout. Seriously. Three hours a day, every day. "You just make a choice to do it," Manion said, between reps from his home gym in rural Montgomery County ...

GSK’s respiratory drug lineup spans a newly approved product for chronic obstructive pulmonary disease as well as therapeutic candidates in various stages of clinical development for treating this ...

GSK’s antibody-drug conjugate strategy may be making more headlines recently, but the British pharma hasn’t forgotten about oligonucleotides. The drugmaker is paying $85 million upfront to Empirico ...

Instead of buying special cleaners or reaching for harsh chemicals to clean around your home, look to your medicine cabinet for a solution. The brown bottle you use for scrapes and cuts is useful in ...

Please provide your email address to receive an email when new articles are posted on . Patients receiving roflumilast vs. azithromycin had a reduced risk for COPD exacerbations at 1 year but an ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

Chronic obstructive pulmonary disease, or COPD, is the fourth leading cause of death worldwide, responsible for 3.5 million deaths in 2021, according to the World Health Organization. It’s a common ...

If you're of a certain age, you probably remember your parents or a nurse bringing out a bottle of hydrogen peroxide to treat your scrapes, cuts, and wounds. This use of the antiseptic is no longer ...

Earwax (cerumen) protects the inside of your ears from irritation and infection. As the body makes new wax, the old earwax usually drains out of your ears naturally. Sometimes earwax can build up and ...

COPD affects at least 4.5% of those 18-49 years old, according to an analysis of U.S. cohorts. The early COPD group was more likely to be hospitalized or die from chronic respiratory disease, to ...

Astegolimab, an anti-ST2 monoclonal antibody designed to block signaling of IL-33 under development by Roche's (OTCQX:RHHBY) Genentech unit, failed to meet its primary endpoint in a phase 3 trial for ...